Novo Nordisk again raises bid in battle for obesity start-up Metsera
Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs
Related reading
Novo Nordisk gatecrashes Pfizer deal with $9bn bid for Metsera
Pfizer had struck deal in September to buy obesity-focused biotech
Battle for obesity biotech Metsera heats up as Pfizer sues to block rival bid
FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk
Pfizer wins $10bn bidding war for weight-loss start-up Metsera
Biotech says it opted for revised offer from US pharma company after rival Novo bid raised antitrust concerns
US regulator warns Novo Nordisk’s Metsera offer ‘may violate’ antitrust law
Federal Trade Commission wants to ensure bid for weight-loss biotech addresses competition concerns
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Pfizer closes in on $7.3bn takeover of anti-obesity drugmaker Metsera
Deal would be the biggest by a large pharma company buying a foothold in the lucrative weight-loss drug market